CTN Trial Progress

Randomizations for Active Studies as of the January 7, 2020 trial Progress Report.

CTN-0067 - CHOICES Scale-Up. Enrolled 116

CTN-0069 - OUD in the Emergency Department. Enrolled 707

Total randomizations in active trials: 823

Protocol Updates

CTN-0079

As a complement to the CTN-0069 study (Opioid Use Disorder in the Emergency Department), CTN-0079 (Emergency Department Connection to Care with Buprenorphine for Opioid Use Disorder) evaluated the feasibility, acceptability, and impact of introducing a clinical protocol for OUD screening, buprenorphine treatment initiation, and referral to ongoing OUD medication treatment in ED settings with high need, limited resources, and differing staffing structures.

The study was completed in three unique clinical sites in New Hampshire and New York. The formative evaluation included staff surveys to assess provider and organizational readiness (Pre: N= 162; Post: N= 155) as well as focus groups/qualitative interviews with staff, patients, and other stakeholders (Pre: N=45; Post: N=43) to learn about feasibility, acceptability, barriers, and facilitators.

Study findings have been presented at CPDD, SAEM, AMERSA, and ACEP. The primary outcome manuscript is anticipated for early 2020. Read more. . .

CTN-0082

Progress on CTN-0082 (Implementation Survey of PrEP and Opioid Use Related Services in STI Clinics and Community Based Organizations) continues, with lead team members from the Pacific Northwest and Greater New York Nodes traveling to Bethesda for the Data Management meeting in mid-January.

CTN-0095

CTN-0095 (Clinic-Randomized Trial of Clinical Decision Support for Opioid Use Disorders in Medical Settings), will be implementing a web-based and electronic health record (EHR)-integrated OUD clinical decision support (CDS) system to offer expert guidance to primary care providers (PCPs) on the diagnosis and management of OUD was developed and piloted. Implementation will occur in three large diverse health care systems and involve randomization of a minimum of 30 clinics to receive the OUD-CDS intervention or usual care (UC). The project will evaluate the impact of OUD CDS on practice process measures and patient outcomes.

Partner sites have been selected and a timeline has been established: Health Partners in July 2020, Geisinger in January 2021, and Duke in July 2021. The Lead Investigators are Rebecca Rossom, M.D., M.S. and Gavin Bart, M.D., Ph.D. Read more. . .

CTN-0097

CTN-0097 (Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT)) is seeking up to 6 community treatment sites that can provide inpatient or residential detoxification services and have the capacity for an on-going outpatient treatment with XR-NTX.

SWIFT compares two methods of initiating treatment with extended-release naltrexone (XR-NTX). The primary goal of this study is to determine whether the Rapid Method (5-7 day long) is non-inferior to a Standard Method (13-day long) on the primary effectiveness outcome of successful initiation of XR-NTX (receiving the first injection).

The Lead Investigators are Drs. Adam Bisaga, Ned Nunes, and John Rotrosen from the Greater New York Node. The deadline for receiving surveys from interested sites is January 21, 2020. For more information and a copy of the survey, please contact Jennifer Lima at jennifer.lima@nyspi.columbia.edu. Read more. . .

CTN-0102

The cluster-randomized clinical trial CTN-0102 (Rural Expansion of Medication Treatment for Opioid Use Disorder) study will evaluate the effectiveness of a program of delivering MOUD (Medication for Opioid Use Disorder) that includes both telemedicine (TM) and OBOT (Office-Based Opioid Treatment) in rural primary care setting.

The study will provide empirical information on whether adding TM to OBOT in the clinic will increase access to and retention in OUD treatment.

The study contains two phases. Phase I, the feasibility and environmental scan study, will examine implementation of TM in 6 rural sites with varying levels of OBOT capacity to inform implementation strategies for the main trial. Phase II, the pragmatic trial, will evaluate the comparative effectiveness between OBOT vs OBOT + TM.

The study team is currently initiating a feasibility study in 6 rural sites in two states and conducting an environmental scan of 40 rural sites for Phase II of this project. Phase II will include approximately 2,400 participants. The Lead Investigator is Dr. Yih-Ing Hser, Ph.D. from the Greater Southern California Node.

Also of Interest

Call for Papers: "Psychology and the Opioid Epidemic" - Special issue of Translational Issues in Psychological Science. TPS is co-sponsored by the American Psychological Association (APA) and the American Psychological Association of Graduate Students (APAGS).

Deadline: April 1, 2020. Read more. . .

Tribal Opioid Overdose Prevention Responses: Community-Based Strategies and Public Health Data Infrastructure from Seven Directions: A Center for Indigenous Public Health is the first document to consider the AI/AN population at the national level, presenting findings from an environmental scan of scientific literature and publicly available web-based information and spotlighting community-based strategies implemented in several states. Read more. . .

Upcoming Events

NAADAC 2020: September 24-29, 2020, Washington DC. Call for presentations now open. Deadline January 22, 2020. Read more. . .

SAVE THE DATE: Addiction Health Services Research (AHSR) conference, October 14-16, 2020 in Providence RI. Hosted by the Center for Alcohol and Addictions Studies at Brown University. Read more. . .